Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270825 | 0.86 | MEN1 (0.37) | KMT2AGAAMEN1 | |
| SCHEMBL24244790 | 0.79 | NNMT (0.42) | KMT2ALMNAALDH1A1MAPTCYP1A2 | |
| SCHEMBL29862129 | 0.77 | — | — | |
| SCHEMBL321951 | 0.77 | — | — | |
| SCHEMBL24244792 | 0.76 | MEN1 (0.35) | KMT2AALDH1A1MEN1 | |
| SCHEMBL4949662 | 0.71 | CHRNA4 (0.39) | KMT2ALMNAALDH1A1MAPTGAA | |
| SCHEMBL22655057 | 0.71 | IL1B (0.46) | KMT2ALMNAALDH1A1MAPTGAA | |
| SCHEMBL2492398 | 0.70 | HTT (0.45) | KMT2AALDH1A1MAPTGAACHRNB2 | |
| SCHEMBL29367162 | 0.69 | — | — | |
| SCHEMBL111337 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104211639-A | Alkynyl heterocyclic compounds and application thereof | SHANGHAI INST MATERIA MEDICA | 2014-12-17 | — | — | CN | disclosed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1058681-B1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM CO LTD (KR) | 2003-05-07 | — | — | EP | disclosed |
| EP-1058681-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | Seoul Pharm. Co., Ltd. (KR) | 2000-12-13 | — | — | EP | disclosed |
| US-5942511-A | PROTECTION OF HUMAN TISSUE FROM RADIATION | Kwon, Soon Kyoung (KR) | 1999-08-24 | — | — | US | disclosed |
| WO-1999036407-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM. CO., LTD. (KR) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | KMT2A 923/4885LMNA 4089/4885ALDH1A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.